The present invention relates, in general terms, to a method of synthesising compounds and a system for synthesising compounds. The method and system can be automated. The method of synthesising a compound includes providing a solid support in fluid communication with a computer-controlled flow system, covalently bonding a first precursor to the solid support, performing at least one reaction, and cleaving the compound from the solid support.

Provided herein are pentafluorobenzenesulfonamide compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Provided herein are RET kinase inhibitors according to the formula: ##STR00001##
pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R.sub.1, n, X.sub.1, X.sub.2, X.sub.3, X.sub.4, and R.sub.2 have the meanings given in the specification.

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH—CO—NH-aryl-O-heteroaryl, for use in treating, ameliorating, delaying, curing and/or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH—CO—NH-aryl-O-heteroaryl, for use in treating, ameliorating, delaying, curing and/or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: ##STR00001##
Also disclosed are pharmaceutical compositions comprising compounds of formula (I).

The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.

The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.